Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer that may be given to reduce death or hospitalization caused by heart problems in adults with cardiomyopathy (damage of the heart muscle) caused by wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM).

VYNDAQEL and VYNDAMAX are prescription medicines used to treat adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) to reduce death and hospitalization related to heart problems.

Aug 14, 2024 · Overview: Vyndaqel is used to treat transthyretin amyloid cardiomyopathy (ATTR-CM). It helps to slow the damage to your heart muscle. There are no known side effects of Vyndaqel. Contact your...

VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. 2. DOSAGE AND ADMINISTRATION.

Tafamidis, sold under the brand names Vyndaqel and Vyndamax, [5] is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis.

Dec 11, 2024 · Vyndaqel contains the micronized meglumine salt of tafamidis, while Vyndamax contains the free acid form of tafamidis. Vyndamax was developed for patient convenience and this formulation allows patients to take just one capsule once per day.

Jan 8, 2025 · VYNDAQEL and VYNDAMAX are prescription medicines used to treat adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) to reduce death and hospitalization related to heart problems.

Feb 7, 2022 · Vyndaqel (tafamidis) is a transthyretin (TTR) stabilizer. It works by attaching to a protein in your body called transthyretin. This slows protein breakdown and buildup in the heart walls, which makes it easier for the heart to pump blood to the rest of your body. Common Brands Vyndaqel, Vyndamax. What are the side effects of Vyndaqel (tafamidis)?

The recommended dosage is either VYNDAQEL 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily or VYNDAMAX 61 mg (one 61-mg tafamidis capsule) orally once daily. VYNDAMAX and VYNDAQEL are not substitutable on a …

In a clinical trial, VYNDAMAX reduced the risk of cardiovascular death as well as hospitalization related to cardiomyopathy. What are the benefits of this drug (results of trials used to assess...